Share ownership Gan & Lee Pharmaceuticals.

603087

CNE100003ZH1

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 05/12/2025			5-day change	1st Jan Change
63.60 ^CNY	+1.92%		-0.11%	+44.22%

11-18	Gan & Lee Pharmaceuticals Europe GmbH Announces Committee for Medicinal Products for Human Use of the European Medicines Agency Recommends the Approval of Insulin Glargine Injection	CI
10-30	Gan & Lee Pharmaceuticals. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI

Share class: Gan & Lee Pharmaceuticals.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	601,065,290	302,429,271 ( 50.32 %)	0	50.32 %

Major shareholders: Gan & Lee Pharmaceuticals.

Name	Equities	%	Valuation
Zhong Ru Gan 39.9 %	211,917,642	39.9 %	2 029 M ¥
Qiming Venture Partners Ltd. 5.162 %	27,414,409	5.162 %	263 M ¥
China Southern Asset Management Co., Ltd. 2.412 %	12,811,468	2.412 %	123 M ¥
China Merchants Fund Management Co., Ltd. 1.198 %	6,359,680	1.198 %	61 M ¥
Xi Ru Gan 1.172 %	6,223,276	1.172 %	60 M ¥
CITIC LIMITED 0.8014 %	4,256,033	0.8014 %	41 M ¥
Jia Zhen Zhang 0.7934 %	4,213,300	0.7934 %	40 M ¥
Yinhua Fund Management Co., Ltd. 0.6602 %	3,506,394	0.6602 %	34 M ¥
Changsheng Fund Management Co., Ltd. 0.6287 %	3,338,733	0.6287 %	32 M ¥
Tian Hong Asset Management Co., Ltd. 0.5994 %	3,183,224	0.5994 %	30 M ¥
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
Zhong Ru Gan 72.27 %	28,508,550	72.27 %	273 M ¥
Hillhouse Investment Management Ltd. (Invest) 10.89 %	4,296,032	10.89 %	41 M ¥

Breakdown by shareholder type

Individuals	47.24%
Institutional	14.44%
CITIC Ltd.	0.8%
Unknown	37.53%

Based on 1000 largest holdings

Geographical origin of shareholders

Individuals	47.24%
China	14.41%
Hong Kong	0.81%
United States	0.01%

Based on 1000 largest holdings

Gan & Lee Pharmaceuticals is a China-based company mainly engaged in the research and development, production and sales of insulin analog APIs and injections. The Company's main products include insulin glargine injection Changxiulin, insulin lispro injection Suxiulin, protamine zinc recombinant insulin lispro mixed injection (25R) Suxiulin 25, Insulin Aspart Injection Ruixilin, Insulin Aspart 30 Injection Ruixilin30, Protamine Human Insulin Mixed Injection (30R) Puxilin30 and many other insulin analogs and human insulin varieties, covering three functional market segments of long-acting, rapid-acting and premixed insulin.

Employees

5,245

Sector

Pharmaceuticals

Calendar

04-22 - Q4 2025 Earnings Release (Projected)

More about the company